{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-18T17:18:33.814730+00:00","company":{"ticker":"CAMP","cik":1736730,"company_name":"Camp4 Therapeutics Corp"},"pagination":{"limit":100,"returned":16,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"ARE-MA Region No. 59, LLC","detail":"lease","count":2,"first_seen":"2025-12-23T23:59:59+00:00","last_seen":"2025-12-23T23:59:59+00:00","evidence_fact_ids":[79320,79321]},{"display_name":"ARE-MA Region No. 75, LLC","detail":"lease","count":1,"first_seen":"2025-12-23T23:59:59+00:00","last_seen":"2025-12-23T23:59:59+00:00","evidence_fact_ids":[79319]},{"display_name":"GlaxoSmithKline Intellectual Property Limited","detail":"collaboration","count":1,"first_seen":"2025-12-18T23:59:59+00:00","last_seen":"2025-12-18T23:59:59+00:00","evidence_fact_ids":[117279]},{"display_name":"Leerink Partners LLC","detail":"underwriting","count":1,"first_seen":"2025-12-18T23:59:59+00:00","last_seen":"2025-12-18T23:59:59+00:00","evidence_fact_ids":[117284]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"8be9faca86bc7804610a590b9ae264795da1ff18","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-06-12T20:10:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"2,773,446","subject":null,"votes_abstain":"199,455","votes_against":"10,023,588","votes_for":"27,002,145","votes_withheld":null}]},"claim":"Camp4 Therapeutics Corp shareholders approved Amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan at the 2026-06-10 meeting.","evidence_excerpt":"3. The stockholders approved the amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan, based on the following votes: For Against Abstain Broker Non-Votes 27,002,145 10,023,588 199,455 2,773,446","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-042846","anchor_url":"https://secwatch.observer/filing/0001628280-26-042846#claim-8be9faca86bc7804610a590b9ae264795da1ff18","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm"},{"fact_type":"shareholder_vote","fact_key":"77cbeb9302c5b7e091a2d34990a01b77df4370e0","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-06-12T20:10:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":null,"votes_against":"127","votes_for":"39,998,507","votes_withheld":null}]},"claim":"Camp4 Therapeutics Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.","evidence_excerpt":"2. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, based on the following votes: For Against Abstain 39,998,507 127 —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-042846","anchor_url":"https://secwatch.observer/filing/0001628280-26-042846#claim-77cbeb9302c5b7e091a2d34990a01b77df4370e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8fcf606da82826ac657c68f72a2b33866fe289f2","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-06-12T20:10:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Election of Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,773,446","subject":"Steven Holtzman","votes_abstain":null,"votes_against":"7,992,146","votes_for":"29,233,042","votes_withheld":null},{"broker_non_votes":"2,773,446","subject":"Murray Stewart, DM FRCP","votes_abstain":"11","votes_against":"5,555,665","votes_for":"31,669,512","votes_withheld":null},{"broker_non_votes":"2,773,446","subject":"Richard Young, PhD","votes_abstain":"12","votes_against":"8,012,214","votes_for":"29,212,962","votes_withheld":null}]},"claim":"Camp4 Therapeutics Corp shareholders approved Election of Class II directors at the 2026-06-10 meeting.","evidence_excerpt":"1. The following nominees were elected as the Company’s Class II directors, each to serve for a three-year term until the 2029 annual meeting of stockholders, and until his successor shall have been duly elected and qualified, based on the following votes: Nominees For Against Abstain Broker Non-Votes Steven Holtzman 29,233,042 7,992,146 — 2,773,446 Murray Stewart, DM FRCP 31,669,512 5,555,665 11 2,773,446 Richard Young, PhD 29,212,962 8,012,214 12 2,773,446","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-042846","anchor_url":"https://secwatch.observer/filing/0001628280-26-042846#claim-8fcf606da82826ac657c68f72a2b33866fe289f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm"},{"fact_type":"earnings_release","fact_key":"1f8f5ed7abb24229012dc46cc5ec86ad6fffdaf8","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter ended March 31, 2026 was $18.3 million, compared to $12.4 million for the quarter ended March 3","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Camp4 Therapeutics Corp reported the first quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026 was $18.3 million, compared to $12.4 million for the quarter ended March 3.","evidence_excerpt":"CAMP4 Therapeutics Corporation (\"CAMP4\") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate highlights.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-032096","anchor_url":"https://secwatch.observer/filing/0001628280-26-032096#claim-1f8f5ed7abb24229012dc46cc5ec86ad6fffdaf8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026032096/0001628280-26-032096-index.htm"},{"fact_type":"earnings_release","fact_key":"60a8af2881af4cd4e1c89ab44c0757fb01db4c2d","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-03-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$80.4 million","period_text":"the year ended December 31, 2025","report_date":"2026-03-05","result_type":"reported_results","revenue_text":null},"claim":"Camp4 Therapeutics Corp reported the year ended December 31, 2025 results: net income $80.4 million.","evidence_excerpt":"Net loss for the year ended December 31, 2025, was $80.4 million compared to $51.8 million for the year ended December 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001736730-26-000015","anchor_url":"https://secwatch.observer/filing/0001736730-26-000015#claim-60a8af2881af4cd4e1c89ab44c0757fb01db4c2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/0001736730-26-000015-index.htm"},{"fact_type":"material_agreement","fact_key":"46b9f743a6acf9cfcfc2960f313f3a7e641103c8","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-12-23T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Cambridge Lease","agreement_type":"lease","counterparty":"ARE-MA Region No. 59, LLC","effective_date":"2025-12-22","item_codes_triggered":["1.01","1.02"],"value_text":"termination date accelerated to 30 days after Watertown Lease Commencement Date"},"claim":"Camp4 Therapeutics Corp terminated Cambridge Lease with ARE-MA Region No. 59, LLC valued at termination date accelerated to 30 days after Watertown Lease Commencement Date (effective 2025-12-22).","evidence_excerpt":"The Lease Amendment will accelerate the termination date of the Cambridge Lease to the date (the “Early Termination Date”) thirty days after the Commencement Date of the Watertown Lease (as such terms are defined below).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001736730-25-000116","anchor_url":"https://secwatch.observer/filing/0001736730-25-000116#claim-46b9f743a6acf9cfcfc2960f313f3a7e641103c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000116/0001736730-25-000116-index.htm"},{"fact_type":"material_agreement","fact_key":"3f7820e39d9f0996f86f9f9ef4684a817e828bf5","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-12-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"First Amendment to Lease Agreement","agreement_type":"lease","counterparty":"ARE-MA Region No. 59, LLC","effective_date":"2025-12-22","item_codes_triggered":["1.01"],"value_text":"accelerates termination date to 30 days after Watertown Lease Commencement Date; base rent abated fr"},"claim":"Camp4 Therapeutics Corp amended First Amendment to Lease Agreement with ARE-MA Region No. 59, LLC valued at accelerates termination date to 30 days after Watertown Lease Commencement Date; base rent abated fr (effective 2025-12-22).","evidence_excerpt":"On December 22, 2025 (the “Effective Date”), CAMP4 Therapeutics Corporation (the “Company”) and ARE-MA Region No. 59, LLC (“ARE 59”) entered into the First Amendment (the “Lease Amendment”) to the Lease Agreement (the “Cambridge Lease”), dated October 3, 2019, by and between the Company and ARE 59.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001736730-25-000116","anchor_url":"https://secwatch.observer/filing/0001736730-25-000116#claim-3f7820e39d9f0996f86f9f9ef4684a817e828bf5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000116/0001736730-25-000116-index.htm"},{"fact_type":"material_agreement","fact_key":"303376cd5af87d1ae57b90983300cde9b9ab4167","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-12-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Lease Agreement","agreement_type":"lease","counterparty":"ARE-MA Region No. 75, LLC","effective_date":"2025-12-22","item_codes_triggered":["1.01"],"value_text":"annual base rent $40.00 per rentable square foot, subject to annual increases of 3%; initial term en"},"claim":"Camp4 Therapeutics Corp entered into Lease Agreement with ARE-MA Region No. 75, LLC valued at annual base rent $40.00 per rentable square foot, subject to annual increases of 3%; initial term en (effective 2025-12-22).","evidence_excerpt":"Also on the Effective Date, the Company entered into a Lease Agreement (the “Watertown Lease”) with ARE-MA Region No. 75, LLC (“ARE 75”), an affiliate of ARE 59, for approximately 44,000 rentable square feet of laboratory and office space located at 100 Talcott Avenue, Watertown, Massachusetts (the “Watertown Premises”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001736730-25-000116","anchor_url":"https://secwatch.observer/filing/0001736730-25-000116#claim-303376cd5af87d1ae57b90983300cde9b9ab4167","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000116/0001736730-25-000116-index.htm"},{"fact_type":"material_agreement","fact_key":"a14a5f1d06131aff8a240e3e2710f566a7b72ad4","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-12-18T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Leerink Partners LLC","effective_date":"2025-12-18","item_codes_triggered":["1.01"],"value_text":"Offering of 5,000,000 shares of common stock at $6.00 per share, net proceeds ~$28.0 million"},"claim":"Camp4 Therapeutics Corp entered into Underwriting Agreement with Leerink Partners LLC valued at Offering of 5,000,000 shares of common stock at $6.00 per share, net proceeds ~$28.0 million (effective 2025-12-18).","evidence_excerpt":"On December 18, 2025, CAMP4 Therapeutics Corporation (the “Company”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC (“ Leerink Partners ”), relating to an offering of 5,000,000 shares (the “ Shares ”), of its common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $6.00 per Share.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001628280-25-058009","anchor_url":"https://secwatch.observer/filing/0001628280-25-058009#claim-a14a5f1d06131aff8a240e3e2710f566a7b72ad4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828025058009/0001628280-25-058009-index.htm"},{"fact_type":"material_agreement","fact_key":"817f6aa1d59548a8872d9e51b5840a64487b5c04","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-12-18T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Research, Collaboration and License Agreement","agreement_type":"collaboration","counterparty":"GlaxoSmithKline Intellectual Property (No. 3) Limited","effective_date":"2025-12-17","item_codes_triggered":["1.01"],"value_text":"$17.5 million"},"claim":"Camp4 Therapeutics Corp entered into Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited valued at $17.5 million (effective 2025-12-17).","evidence_excerpt":"On December 17, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Research, Collaboration and License Agreement (the “Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001736730-25-000111","anchor_url":"https://secwatch.observer/filing/0001736730-25-000111#claim-817f6aa1d59548a8872d9e51b5840a64487b5c04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/0001736730-25-000111-index.htm"},{"fact_type":"equity_issuance","fact_key":"bf706e9557376c3821be30fe06c946f4d62f1dfc","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-09-10T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"a purchase price of $1.65 per share","effective_date":"2025-09-11","item_codes_triggered":["3.02"],"purchaser":"certain members of management including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young and Leonard Zon","security_type":"common_stock","shares_text":"an additional 36,361 Shares"},"claim":"Camp4 Therapeutics Corp issued an additional 36,361 Shares of common stock to certain members of management including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young and Leonard Zon for a purchase price of $1.65 per share.","evidence_excerpt":"the Company will issue and sell to certain members of management, including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young, who also serves as a director on the Company’s Board of Directors (the “ Board ”) and Leonard Zon, who serves as a Board observer, an additional 36,361 Shares at a purchase price of $1.65 per share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001736730-25-000072","anchor_url":"https://secwatch.observer/filing/0001736730-25-000072#claim-bf706e9557376c3821be30fe06c946f4d62f1dfc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm"},{"fact_type":"equity_issuance","fact_key":"9b698b61aa4863c1f71299fbde24791f01679eff","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-09-10T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$1.5299 per pre-funded warrant","effective_date":"2025-09-11","item_codes_triggered":["3.02"],"purchaser":"certain accredited investors","security_type":"warrant","shares_text":"pre-funded warrants to purchase 6,003,758 shares of Common Stock"},"claim":"Camp4 Therapeutics Corp issued pre-funded warrants to purchase 6,003,758 shares of Common Stock of warrant to certain accredited investors for $1.5299 per pre-funded warrant.","evidence_excerpt":"in lieu of Common Stock to certain Investors, pre-funded warrants to purchase 6,003,758 shares of Common Stock (the “ Warrant Shares ” and, together with the Shares, the “ Securities ”) at an offering price of $1.5299 per pre-funded warrant (the “ Pre-Funded Warrant Price ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001736730-25-000072","anchor_url":"https://secwatch.observer/filing/0001736730-25-000072#claim-9b698b61aa4863c1f71299fbde24791f01679eff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm"},{"fact_type":"equity_issuance","fact_key":"41e1ee188db99092f7b5a8354746ed1a17e1fa8d","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-09-10T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$1.53 per Share","effective_date":"2025-09-11","item_codes_triggered":["3.02"],"purchaser":"certain accredited investors","security_type":"common_stock","shares_text":"26,681,053 shares"},"claim":"Camp4 Therapeutics Corp issued 26,681,053 shares of common stock to certain accredited investors for $1.53 per Share.","evidence_excerpt":"At the Initial Closing, the Company has agreed to issue and sell 26,681,053 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $1.53 per Share (the “ Share Price ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001736730-25-000072","anchor_url":"https://secwatch.observer/filing/0001736730-25-000072#claim-41e1ee188db99092f7b5a8354746ed1a17e1fa8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm"},{"fact_type":"executive_change","fact_key":"5a930c9529","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-17","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Douglas Williams was appointed as Class I Director at Camp4 Therapeutics Corp.","evidence_excerpt":"appointed Douglas Williams, PhD as a Class I director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001736730-25-000004","anchor_url":"https://secwatch.observer/filing/0001736730-25-000004#claim-5a930c9529","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000004/0001736730-25-000004-index.htm"},{"fact_type":"governance_change","fact_key":"0dcbd710cb408b3d99e284ab3506f018bbdd1575","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2024-10-15T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-10-15","item_codes_triggered":["5.03"],"summary_text":"Adopted amended and restated bylaws to establish procedures for stockholder proposals and director nominations, modify indemnification provisions, and conform to the amended charter."},"claim":"Camp4 Therapeutics Corp: Adopted amended and restated bylaws to establish procedures for stockholder proposals and director nominations, modify indemnification provisions, and conform to the amended charter (effective 2024-10-15).","evidence_excerpt":"On October 15, 2024, in connection with the consummation of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors and stockholders, became effective.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-108583","anchor_url":"https://secwatch.observer/filing/0001104659-24-108583#claim-0dcbd710cb408b3d99e284ab3506f018bbdd1575","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/0001104659-24-108583-index.htm"},{"fact_type":"governance_change","fact_key":"ce7e89cc2b508ee092782c190db242529ce916e5","cik":1736730,"ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","filed_at":"2024-10-15T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-10-15","item_codes_triggered":["5.03"],"summary_text":"Filed fifth amended and restated certificate of incorporation to increase authorized common stock, eliminate references to existing preferred, authorize undesignated preferred stock, and eliminate stockholder action by written consent."},"claim":"Camp4 Therapeutics Corp: Filed fifth amended and restated certificate of incorporation to increase authorized common stock, eliminate references to existing preferred, authorize undesignated preferred stock, and eliminate stockholder action by written consent (effective 2024-10-15).","evidence_excerpt":"On October 15, 2024, in connection with the consummation of the initial public offering (the “IPO”) of shares of common stock, par value $0.0001 per share (“Common Stock”), of CAMP4 Therapeutics Corporation (the “Company”), the Company filed a fifth amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware, which became effective upon filing.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-108583","anchor_url":"https://secwatch.observer/filing/0001104659-24-108583#claim-ce7e89cc2b508ee092782c190db242529ce916e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/0001104659-24-108583-index.htm"}]}